The earnings call presented a mixed picture with significant clinical progress and a strong cash position highlighting the positives. However, increased net losses and rising expenditures underscore financial challenges. The call reflects a balanced perspective of achievements and operational costs.

Company Guidance -

Q3 2025

During the Viking Therapeutics Second Quarter 2025 Financial Results Conference Call, the company provided detailed guidance on their clinical development activities and financial performance. Viking advanced its VK2735 program, initiating the VANQUISH Phase III registration study for the subcutaneous formulation targeting obesity and completed enrollment in a Phase II trial for the oral tablet. The Phase II VENTURE study showed up to 14.7% weight loss, with VK2735 demonstrating safety and tolerability. Viking also progressed its amylin receptor agonist program, aiming to file an IND by Q4 2025. Financially, research and development expenses rose to $60.2 million for Q2 2025, compared to $23.8 million in Q2 2024, reflecting increased clinical and manufacturing activities. General and administrative expenses increased to $14.4 million from $10.3 million in the same period last year. Viking reported a net loss of $65.6 million or $0.58 per share for Q2 2025, with $808 million in cash and investments as of June 30, 2025, supporting their ongoing clinical advancements.

Advancement of VK2735 into Phase III

Viking Therapeutics announced the initiation of the VANQUISH Phase III registration program for VK2735, targeting obesity and type 2 diabetes, indicating significant progress in their clinical pipeline.

Completion of Enrollment for Phase II Oral Trial

The company completed enrollment in a Phase II trial for the oral formulation of VK2735, highlighting rapid enrollment and strong demand for new weight loss therapies.

Strong Cash Position

Viking Therapeutics reported $808 million in cash, cash equivalents, and short-term investments, providing a solid financial runway to support ongoing clinical trials and development programs.

Positive Phase II Results for VK2735

The VENTURE Phase II study achieved its primary and secondary endpoints, showing statistically significant weight loss of up to 14.7% and good safety profiles for VK2735.

Progress in Amylin Receptor Program

Viking made strides with its novel amylin receptor agonist program, with an IND filing expected in the fourth quarter, supporting further pipeline diversification.

Viking Therapeutics (VKTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VKTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 22, 2025	2025 (Q3)	-0.67 / -	-0.22	―	―	―
Jul 24, 2025	2025 (Q2)	-0.45 / -0.58	-0.2	-190.00% (-0.38)	―
Apr 23, 2025	2025 (Q1)	-0.33 / -0.41	-0.26	-57.69% (-0.15)	―
Feb 05, 2025	2024 (Q4)	-0.28 / -0.32	-0.25	-28.00% (-0.07)	―
Oct 23, 2024	2024 (Q3)	-0.24 / -0.22	-0.23	4.35% (+0.01)	―
Jul 24, 2024	2024 (Q2)	-0.26 / -0.20	-0.19	-5.26% (-0.01)	―
Apr 24, 2024	2024 (Q1)	-0.28 / -0.26	-0.25	-4.00% (-0.01)	―
Feb 07, 2024	2023 (Q4)	-0.25 / -0.25	-0.26	3.85% (+0.01)	―
Oct 25, 2023	2023 (Q3)	-0.22 / -0.23	-0.21	-9.52% (-0.02)	―
Jul 26, 2023	2023 (Q2)	-0.19 / -0.19	-0.23	17.39% (+0.04)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VKTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 24, 2025	$33.50	$34.42	+2.75%
Apr 23, 2025	$25.79	$25.66	-0.50%
Feb 05, 2025	$33.50	$31.46	-6.09%
Oct 23, 2024	$60.39	$73.22	+21.25%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Viking Therapeutics (VKTX) report earnings?

Viking Therapeutics (VKTX) is schdueled to report earning on Oct 22, 2025, After Close (Confirmed).

What is Viking Therapeutics (VKTX) earnings time?

Viking Therapeutics (VKTX) earnings time is at Oct 22, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VKTX EPS forecast?

VKTX EPS forecast for the fiscal quarter 2025 (Q3) is -0.67.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing